Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a promising oncology-focused biopharmaceutical company with a diverse portfolio and strong market position. Their lead asset BRUKINSA has shown growth and potential for future success, leading analysts to maintain a BUY rating. The company's revenue is expected to increase due to the success of BRUKINSA and new market expansion, and upcoming catalysts point to potential for future growth.

Bears say

BeOne Medicines is currently facing material sustainability issues such as implementing green manufacturing processes, data transparency, and socially responsible drug pricing. These issues can potentially affect the company's financial performance and hinder its growth potential. Additionally, the company's financial results for the first quarter of 2026 exceeded expectations, however, its financial guidance for the full year was only slightly increased and may not be enough to sustain the company's growth and address its sustainability concerns. With these factors in mind, a negative outlook on BeOne Medicines stock may be warranted as the company's future success and potential may be limited by its sustainability challenges and cautious financial outlook.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $387, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $387, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.